DNA tumor viruses are capable of driving quiescent cells into the cell cycle. In case of polyomaviridae, two viral proteins, the large and the small (ST) T antigens are responsible for this outcome. ST interacts with the protein phosphatase PP2A and with chaperons of the dnaK type and leads to the transactivation of several genes, which play a role in S-phase induction. One of these is the transcription factor myelocytomatosis (MYC), which by itself is an important regulator of growth. Microarray analysis has revealed several ST-induced genes, which are also targets of MYC; hence, ST may induce these genes via MYC. Experiments shown here are in line with this assumption. MYC-regulated genes are induced by ST at later times than MYC and a MYC responsive promoter is stimulated by ST. Regulation of MYC occurs through signal transduction pathways, which are co-ordinated by PP2A suggesting that they may be targets of ST. Here, we show that this is the case as important kinases involved in these pathways appear in the active phosphorylated form in the presence of ST. Inhibition of these kinases interferes with MYC induction and inhibition of MYC activity blocks ST-mediated transactivation.
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The multiple-stage process of cancer development is driven by genetic and epigenetic events. Cancer can also be associated with virus infection, for instance, with members of the small DNA tumor virus family. The role of human papillomaviruses in the development of carcinomas of the cervix is well documented and a contribution of polyomaviridae, Simian virus 40 (SV40) or the human polyomaviruses, BKV and JCV, in the etiology of human cancers has frequently been considered (Reiss and Khalili, 2003) . Up to 80% of the human population carries information of human polyomaviruses, but it is so far unproven that these viruses play a causative role in the formation of cancers. However, polyomaviruses have been extremely helpful in studies of cell cycle regulation and cell transformation. This includes the discovery of important cellular regulators such as p53 or the retinoblastoma protein pRB (Moran, 1993) .
All polyomaviruses code for two major early proteins, the small (ST) and the large (LT) tumor antigen. Polyomaviruses can infect a variety of cell types including differentiated and hence growth arrested cells. As they depend on the cellular machinery for replication of their DNA, the T antigens meet this prerequisite by interfering with the growth control of the host cell, driving cells into the S-phase of the cell cycle. These reactions may form the basis for the tumorigenic capacity of these viruses.
The contribution of LT oncogene to S-phase induction consists of the transactivation of E2F-regulated genes, which requires interactions of the viral protein with the pocket proteins (pRB and its relatives p130 and p107; Harbour and Dean (2000) ) with chaperons such as HSC70 (Sullivan and Pipas, 2002) and with the coactivator proteins CBP/p300 (Nemethova et al., 2004) .
The main cellular interactors of ST antigen are the protein phosphatase PP2A (Yang et al., 1991) and chaperons. PP2A is trimeric, consisting of a catalytic subunit C and two regulatory subunits A and B. B subunits constitute a family of proteins whereof individual members are assumed to confer substrate specificity to the phosphatase (Millward et al., 1999; Virshup, 2000) . ST proteins can replace distinct B subunits (Chen et al., 2004) , which results in an inactivation of PP2A with respect to specific substrates. Among these substrates is, for instance, p27
Kip1 an inhibitor of the cyclin-dependent kinase cdk2 (Porras et al., 1999; Schu¨chner and Wintersberger, 1999) . ST has been shown to stimulate signal transduction pathways (Sontag et al., 1993; Frost et al., 1994; Howe et al., 1998) and to transactivate genes, for example telomerase, cyclin D1 (Watanabe et al., 1996) and cyclin A (Porras et al., 1996; Schu¨chner et al., 2001) . Thus, ST contributes importantly to S-phase induction. Indeed it was found that neither LT nor ST by itself can induce an S-phase in growth-arrested mouse or human fibroblasts, but that the two proteins together do so quite effectively (Ogris et al., 1992; Porras et al., 1999) . This result was substantiated more recently when it was found that stable transfection of a combination of oncogenic Ras, telomerase and SV40 LT and ST antigen can transform human cells; LT alone was not sufficient for this reaction (Yu et al., 2001; Hahn et al., 2002) .
Microarray analysis was carried out to more fully comprehend the capacity of ST and LT proteins to deregulate the transcriptional program of the host cell (Klucky et al., 2004) . This showed that both proteins affect transcription of a surprisingly large number of genes. Interestingly, among the proteins found transcriptionally upregulated by ST was the transcription factor myelocytomatosis (MYC). Intact binding sites for PP2A and chaperons (J domain) were found essential for this reaction. This finding led us to propose that the induction of a variety of genes seen in the microarray study may be a consequence of the upregulation of MYC (Klucky et al., 2004) .
MYC dimerizes with MAX to bind specifically to a DNA sequence, called E-box, present in promoters of many genes. Thereby MYC controls the expression of genes involved in proliferation, differentiation and apoptosis (Levens, 2003; Pelengaris and Khan, 2003; Patel et al., 2004) . We found concurrencies by comparing data of the microarray analysis of cells expressing ST with the results of genome-wide investigations of MYCregulated genes. For instance, like MYC, PyST upregulates several ribosomal proteins, heat shock proteins, nucleolin, cyclins and telomerase (Klucky et al., 2004) . Induction of all of these presumptive MYC targets was found to depend on an interaction of ST with PP2A and chaperons. If these genes were indeed secondary targets of ST-induced MYC, their mRNA levels should increase later than that of MYC. As shown in Figure 1a , this is indeed the case. In Swiss 3T3 mouse fibroblasts, which conditionally express ST under the direction of the MMTV promoter (Ogris et al., 1992) , ST mRNA is induced already 4 h after addition of dexamethasone to serum-starved cells. MYC mRNA also increases already 4 h after addition of dexamethasone and reaches a maximum level after 20 h. mRNAs for telomerase (TERT) and cyclin D1 increase later, which is in line with the assumption that they are targets of MYC. If this were so, one would expect that a reporter gene fibroblast and derived cell lines, conditionally expressing PyST wild type or mutants under the control of the Dexamethasone-inducible MMTV promoter, was grown as described (Ogris et al., 1992) . Growth arrest and further treatment of cells, isolation of RNA and quantitative PCR were carried out as described previously (Klucky et al., 2004) Polyoma ST transactivates genes through induction of MYC B Klucky and E Wintersberger under an artificial promoter containing a MYC-responsive E-box should be transactivated by ST. Figure 1b shows that this is the case. As expected, activation of this promoter depends on intact binding sites for PP2A and chaperons.
Deregulated expression of MYC is found in many human tumors (Nesbit et al., 1999) and multiple signal transduction pathways are implicated in the activation of MYC, among these are the RAS effector pathways, PI3K/AKT and MAPK. Recently, two kinases were found to be crucial in the activation, the stabilization and eventually the inactivation of MYC (Sears et al., 2000 , Yeh et al., 2004 . Phosphorylated and hence active extracellular-signal-regulated kinase (ERK) phosphorylates MYC at serine 62, which results in an activation and a stabilization of the transcription factor. GSK3b, which in its phosphorylated form is inactive, can phosphorylate MYC on threonine 58 only when the RAS pathway is shut off. This leads to MYC degradation by the ubiquitine/proteasome pathway. Removal of the phosphate from serine 62 in a doubly phosphorylated MYC (serine 62 and threonine 58) by PP2A resulting in a threonine 58 monophosphorylated species of the transcription factor is a prerequisite for degradation (Yeh et al., 2004) .
In growth-arrested cells ST-induced upregulation of particular steps of these pathways may render them independent of external growth signals. Consequently, we have analysed several kinases with respect to their phosphorylation status in the presence and absence of ST protein. Our data strongly indicate that ST activates the AKT pathway by altering the function of PP2A, leading to the appearance of phosphorylated forms of AKT and TOR (Figure 2a) . PI3K was shown to be activated by the SV40 ST, leading to PKC and mitogen activated protein kinase (MEK) activation (Sontag et al., 1993) and cDNA microarray analysis showed that polyomavirus ST increases mRNA levels of the p85 regulatory subunit of PI3-kinase (Klucky et al., 2004) . ST can furthermore be shown to cause the emergence of phosphorylated and hence activated versions of MEK and ERK kinases in serum-starved cells (Figure 2b ). By giving rise to an accumulation of phosphorylated ERK, ST specifically creates exactly those conditions, which result in an activation and stabilization of MYC. The negatively active kinase, GSK3b, remains inactive because the RAS pathways will be active as long as ST inactivates PP2A. Since PP2A is also required for the removal of phosphate from serine 62 of MYC, ST will inhibit this reaction as well and thus will keep MYC in stable and active form. In fact, as shown in Figure 2d , MYC protein increases with time in cells expressing ST and accumulates further even when MYC mRNA starts already to decline (see Figure 1a) , which is in accord with MYC stabilization. Taken together, ST, by its capacity to activate RAS pathways, is competent to create those conditions, which activate and stabilize MYC Support for this conclusion comes from experiments shown in Figure 3a , where the ST-induced conversion of the kinases to their phosphorylated form is inhibited by specific kinase inhibitors. Under these conditions neither MYC nor its target genes, cyclin D1 and TERT, are induced by ST (Figure 3b ). On the other hand, if MYC is induced by ST in the presence of a MYC inhibitor, which competes with the transcription factor for binding to the E box in MYC-regulated promoters, no transactivation of the two target genes, cyclin D and TERT, can be observed (Figure 3b) , which underlines the conclusion that upregulation of these genes by ST indeed occurs via MYC. Finally, ST interferes with WNT signalling by upregulating the major key regulator of the pathway, b-catenin (Figure 2c ), which itself is involved in MYC induction. Polyoma ST decreases cadherin 11 and E cadherin mRNA (Klucky et al., 2004) and protein ( Figure 2c ) and may thereby prevent cadherin/ b-catenin complex formation, resulting in an increase in b-catenin in the cytoplasm (Figure 2c ). Owing to the upregulation of RAS signal transduction pathways by ST, GSK3b, the kinase, which within the APC complex is responsible for phosphorylating and thereby destabilizing b-catenin, is inactive. b-Catenin thus remains stable and is transported into the nucleus where it binds to T-cell factor (TCF) and activates transcription of many genes including MYC (Barker et al., 2000) . In accordance with this proposed sequence of events, ST can be shown to strongly induce the expression of a transgene under a TCF-responsive promoter (Figure 3c ), which proves the involvement of b-catenin in ST-mediated production of MYC. Altogether the outcome is a strong activation of the expression and a stabilization of MYC.
An independent study also came to the conclusion that MYC is a major target of ST protein. In this work, the role of phosphorylation and dephosphorylation of MYC was studied and PP2A was found to play an important role in the switch from stabilization to degradation of MYC (Yeh et al., 2004 , see also the above discussion). As expected, inhibition of PP2A by ST resulted in continuously high and active MYC. Even more interesting is that a mutated version of MYC, which escapes regulated destruction, can replace ST in the transformation system consisting of mutated Ras, telomerase and SV40 LT and ST proteins (Yeh et al., 2004) . This provides strong support for the conclusion that the induction of MYC is a central function of ST in transformation and S-phase induction. By addressing PP2A, ST interferes with the function of a central regulator of signal transduction and cell cycle control. It is interesting to note that in contrast to ST, LT does not upregulate MYC in arrested cells (Klucky et al., 2004) . Thus, LT and ST deal with two different transcription systems leading to S-phase induction, which, at least in part, explains the requirement of both viral proteins in this process. Experiments were carried out as in Figure 2 except that 50 mM AKT inhibitor (PI3 kinase inhibitor LY294002, Cell signalling #9901), or 10 mM MEK inhibitor (UO126, Cell signalling #999) were added 1 h before cell harvesting. (b) Kinase inhibitors and MYC inhibitor block ST-induced transactivation of TERT and cyclin D1. Kinase inhibitors were used as in (a), MYC inhibitor (10 mM H1-S6A, F8A from Biomol Res. Lab. Plymouth Meeting, PA, USA) was added together with Dexamethasone to serum-starved 3T3ST cells for 28 h. Semiquantitative RT-PCR was performed as described (Klucky et al., 2004) . HPRT served as loading control. (c) ST activates b-catenin-dependent TCF transcription factor. TCF reporter construct (wt or mutant from Upstate, Charlottesville, VA, USA #17-285) was cotransfected with pCIneoSTwt or mutants into REF 52 cells. Assays were carried out as in Figure 1b .
